Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells

Wei Dong Chen, James Eshleman, M. Reza Aminoshariae, Ai Hong Ma, Neil Veloso, Sanford D. Markowitz, W. David Sedwick, Martina L. Veigl

Research output: Contribution to journalArticle

Abstract

Background: Deficiency of DNA mismatch repair is a common feature of cancers exhibiting instability of microsatellite DNA sequences. Cancers with microsatellite instability are recognizable by their high rate of spontaneous frameshift mutations within microsatellite sequences, their resistance to killing by cytotoxic agents, and their localization to specific tissues, e.g., the proximal colon and stomach. We hypothesized that the mismatch repair deficiency of these cancers would make them vulnerable to environmental or chemical frameshift-inducing agents. This study was undertaken to test whether exogenous frameshift-inducing agents selectively induce mutations in mismatch repair-deficient cells of mutagen-exposed tissues like the colon and whether cytotoxic doses of these agents would preferentially kill those cells. Methods: Cytotoxicity of the acridine mutagen 6-chloro-9-[3-(2-chloro-ethylamino)propylamino]-2-methoxy-acridine (ICR191), a DNA frameshift inducer, was determined in the mismatch repair- deficient human colon carcinoma cell line HCT116 versus the repair- reconstituted derivative HCTl16+C3. Vulnerability to the mutagenic effects of ICR191 was determined by transfection of HCT116 or HCT116+C3 cells with a frameshift reporter vector, followed by treatment of the cells with ICR191. Alternatively, the reporter vector was reacted ex vivo with ICR191, and the derivatized vector was then transfected into HCT116 or HCT116+C3 cells. Results: ICR191 proved to be fivefold to 10-fold more potent in inducing mutations in mismatch repair-deficient HCT116 cells than in mismatch repair- proficient HCT116+C3 cells. Moreover, at cytotoxic doses of ICR191, repair- deficient HCT116 cells proved to be fivefold more vulnerable to killing than did HCT116+C3 cells. Conclusions: Frameshift-inducing mutagens can selectively induce mutations in mismatch repair-deficient cells versus mismatch repair-proficient cells. Environmental exposures may, therefore, favor development of cancers with microsatellite instability in tissues like the gut. Frameshift-inducing agents can, however, also preferentially kill mismatch repair-deficient cancer cells and, thus, may be promising as model therapeutic compounds.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalJournal of the National Cancer Institute
Volume92
Issue number6
StatePublished - Mar 15 2000

Fingerprint

DNA Mismatch Repair
HCT116 Cells
Colonic Neoplasms
Microsatellite Instability
Mutagens
Acridines
Colon
Cytotoxins
Neoplasms
Mutation
Frameshift Mutation
Environmental Exposure
Microsatellite Repeats
Transfection
Stomach
Carcinoma
Cell Line
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, W. D., Eshleman, J., Aminoshariae, M. R., Ma, A. H., Veloso, N., Markowitz, S. D., ... Veigl, M. L. (2000). Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. Journal of the National Cancer Institute, 92(6), 480-485.

Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. / Chen, Wei Dong; Eshleman, James; Aminoshariae, M. Reza; Ma, Ai Hong; Veloso, Neil; Markowitz, Sanford D.; Sedwick, W. David; Veigl, Martina L.

In: Journal of the National Cancer Institute, Vol. 92, No. 6, 15.03.2000, p. 480-485.

Research output: Contribution to journalArticle

Chen, WD, Eshleman, J, Aminoshariae, MR, Ma, AH, Veloso, N, Markowitz, SD, Sedwick, WD & Veigl, ML 2000, 'Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells', Journal of the National Cancer Institute, vol. 92, no. 6, pp. 480-485.
Chen, Wei Dong ; Eshleman, James ; Aminoshariae, M. Reza ; Ma, Ai Hong ; Veloso, Neil ; Markowitz, Sanford D. ; Sedwick, W. David ; Veigl, Martina L. / Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. In: Journal of the National Cancer Institute. 2000 ; Vol. 92, No. 6. pp. 480-485.
@article{d3be2ae57f364ef2a4f1c0b736251759,
title = "Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells",
abstract = "Background: Deficiency of DNA mismatch repair is a common feature of cancers exhibiting instability of microsatellite DNA sequences. Cancers with microsatellite instability are recognizable by their high rate of spontaneous frameshift mutations within microsatellite sequences, their resistance to killing by cytotoxic agents, and their localization to specific tissues, e.g., the proximal colon and stomach. We hypothesized that the mismatch repair deficiency of these cancers would make them vulnerable to environmental or chemical frameshift-inducing agents. This study was undertaken to test whether exogenous frameshift-inducing agents selectively induce mutations in mismatch repair-deficient cells of mutagen-exposed tissues like the colon and whether cytotoxic doses of these agents would preferentially kill those cells. Methods: Cytotoxicity of the acridine mutagen 6-chloro-9-[3-(2-chloro-ethylamino)propylamino]-2-methoxy-acridine (ICR191), a DNA frameshift inducer, was determined in the mismatch repair- deficient human colon carcinoma cell line HCT116 versus the repair- reconstituted derivative HCTl16+C3. Vulnerability to the mutagenic effects of ICR191 was determined by transfection of HCT116 or HCT116+C3 cells with a frameshift reporter vector, followed by treatment of the cells with ICR191. Alternatively, the reporter vector was reacted ex vivo with ICR191, and the derivatized vector was then transfected into HCT116 or HCT116+C3 cells. Results: ICR191 proved to be fivefold to 10-fold more potent in inducing mutations in mismatch repair-deficient HCT116 cells than in mismatch repair- proficient HCT116+C3 cells. Moreover, at cytotoxic doses of ICR191, repair- deficient HCT116 cells proved to be fivefold more vulnerable to killing than did HCT116+C3 cells. Conclusions: Frameshift-inducing mutagens can selectively induce mutations in mismatch repair-deficient cells versus mismatch repair-proficient cells. Environmental exposures may, therefore, favor development of cancers with microsatellite instability in tissues like the gut. Frameshift-inducing agents can, however, also preferentially kill mismatch repair-deficient cancer cells and, thus, may be promising as model therapeutic compounds.",
author = "Chen, {Wei Dong} and James Eshleman and Aminoshariae, {M. Reza} and Ma, {Ai Hong} and Neil Veloso and Markowitz, {Sanford D.} and Sedwick, {W. David} and Veigl, {Martina L.}",
year = "2000",
month = "3",
day = "15",
language = "English (US)",
volume = "92",
pages = "480--485",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells

AU - Chen, Wei Dong

AU - Eshleman, James

AU - Aminoshariae, M. Reza

AU - Ma, Ai Hong

AU - Veloso, Neil

AU - Markowitz, Sanford D.

AU - Sedwick, W. David

AU - Veigl, Martina L.

PY - 2000/3/15

Y1 - 2000/3/15

N2 - Background: Deficiency of DNA mismatch repair is a common feature of cancers exhibiting instability of microsatellite DNA sequences. Cancers with microsatellite instability are recognizable by their high rate of spontaneous frameshift mutations within microsatellite sequences, their resistance to killing by cytotoxic agents, and their localization to specific tissues, e.g., the proximal colon and stomach. We hypothesized that the mismatch repair deficiency of these cancers would make them vulnerable to environmental or chemical frameshift-inducing agents. This study was undertaken to test whether exogenous frameshift-inducing agents selectively induce mutations in mismatch repair-deficient cells of mutagen-exposed tissues like the colon and whether cytotoxic doses of these agents would preferentially kill those cells. Methods: Cytotoxicity of the acridine mutagen 6-chloro-9-[3-(2-chloro-ethylamino)propylamino]-2-methoxy-acridine (ICR191), a DNA frameshift inducer, was determined in the mismatch repair- deficient human colon carcinoma cell line HCT116 versus the repair- reconstituted derivative HCTl16+C3. Vulnerability to the mutagenic effects of ICR191 was determined by transfection of HCT116 or HCT116+C3 cells with a frameshift reporter vector, followed by treatment of the cells with ICR191. Alternatively, the reporter vector was reacted ex vivo with ICR191, and the derivatized vector was then transfected into HCT116 or HCT116+C3 cells. Results: ICR191 proved to be fivefold to 10-fold more potent in inducing mutations in mismatch repair-deficient HCT116 cells than in mismatch repair- proficient HCT116+C3 cells. Moreover, at cytotoxic doses of ICR191, repair- deficient HCT116 cells proved to be fivefold more vulnerable to killing than did HCT116+C3 cells. Conclusions: Frameshift-inducing mutagens can selectively induce mutations in mismatch repair-deficient cells versus mismatch repair-proficient cells. Environmental exposures may, therefore, favor development of cancers with microsatellite instability in tissues like the gut. Frameshift-inducing agents can, however, also preferentially kill mismatch repair-deficient cancer cells and, thus, may be promising as model therapeutic compounds.

AB - Background: Deficiency of DNA mismatch repair is a common feature of cancers exhibiting instability of microsatellite DNA sequences. Cancers with microsatellite instability are recognizable by their high rate of spontaneous frameshift mutations within microsatellite sequences, their resistance to killing by cytotoxic agents, and their localization to specific tissues, e.g., the proximal colon and stomach. We hypothesized that the mismatch repair deficiency of these cancers would make them vulnerable to environmental or chemical frameshift-inducing agents. This study was undertaken to test whether exogenous frameshift-inducing agents selectively induce mutations in mismatch repair-deficient cells of mutagen-exposed tissues like the colon and whether cytotoxic doses of these agents would preferentially kill those cells. Methods: Cytotoxicity of the acridine mutagen 6-chloro-9-[3-(2-chloro-ethylamino)propylamino]-2-methoxy-acridine (ICR191), a DNA frameshift inducer, was determined in the mismatch repair- deficient human colon carcinoma cell line HCT116 versus the repair- reconstituted derivative HCTl16+C3. Vulnerability to the mutagenic effects of ICR191 was determined by transfection of HCT116 or HCT116+C3 cells with a frameshift reporter vector, followed by treatment of the cells with ICR191. Alternatively, the reporter vector was reacted ex vivo with ICR191, and the derivatized vector was then transfected into HCT116 or HCT116+C3 cells. Results: ICR191 proved to be fivefold to 10-fold more potent in inducing mutations in mismatch repair-deficient HCT116 cells than in mismatch repair- proficient HCT116+C3 cells. Moreover, at cytotoxic doses of ICR191, repair- deficient HCT116 cells proved to be fivefold more vulnerable to killing than did HCT116+C3 cells. Conclusions: Frameshift-inducing mutagens can selectively induce mutations in mismatch repair-deficient cells versus mismatch repair-proficient cells. Environmental exposures may, therefore, favor development of cancers with microsatellite instability in tissues like the gut. Frameshift-inducing agents can, however, also preferentially kill mismatch repair-deficient cancer cells and, thus, may be promising as model therapeutic compounds.

UR - http://www.scopus.com/inward/record.url?scp=0034653705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034653705&partnerID=8YFLogxK

M3 - Article

C2 - 10716966

AN - SCOPUS:0034653705

VL - 92

SP - 480

EP - 485

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -